戻る Agenda
SESSION 1 : Regenerative Movements in New Drug Development to Provide Innovative Medicine to Patients in Asia and Worldwide
Session Chair(s)
Junko Sato, PhD
Associate Executive Director, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Masafumi Yokota, DVM, PhD
Senior Director , Daiichi Sankyo Co., Ltd., Japan
Speaker(s)
Singapore’s Regulatory Approach towards Clinical Genetics and Precision Medicine Services
Raymond Chua, MD, MBA, MPH, FRCP
Chief Executive Officer, Health Sciences Authority, Singapore
Digital Transformation in New Drug Development Worldwide: A US FDA Perspective
Theresa Mullin, PhD
Associate Center Director - CDER, FDA, United States
Digital Transformation of New Drug Development in JAPAN
Yasuhiro Fujiwara, MD, PhD
Chief Executive, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Digital Transformation in New Drug Development NMPA Perspective and Practice
Shi Le
Department of Drug Registration, National Medical Products Administration, China
Korea’s Perspective on Innovative Medicine to Patients
Mee Ryung Ahn, PhD
Director, Ministry of Food and Drug Safety, Korea, Republic of